Orris

Ra ILD full details for md exams 15marks answer from fishman and murray and ats and ers guidelines just from these only

Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
This is a complete, exam-ready 15-mark answer drawn exclusively from Fishman's Pulmonary Diseases and Disorders (Chapter 58, pp. 1025-1030) and Murray & Nadel's Textbook of Respiratory Medicine (Chapter 92, pp. 2091-2094). Here are the high-yield points to not miss:
Exam traps and must-knows:
  1. Male predominance (3:1) - opposite to most other CTD-ILDs which are female-predominant
  2. Pleural glucose <30 mg/dL - virtually pathognomonic; only RA or empyema gives this
  3. ILD can precede arthritis by months to years - in up to 20% of patients
  4. UIP in RA = worse prognosis than NSIP, but still better than idiopathic IPF in 25% of patients
  5. MUC5B variant - the key genetic predisposition for RA-UIP specifically
  6. Nintedanib is the only approved-level evidence agent for progressive fibrosing RA-ILD (IN-BUILD trial)
  7. BAL neutrophil + eosinophil predominance = poor prognostic marker (underlying UIP)
  8. Caplan syndrome = RA + pneumoconiosis + upper lobe nodules in crops
  9. Acute exacerbations are more common in RA-ILD than in other CTD-ILDs, and carry high early mortality
  10. High-dose corticosteroids should be used with caution when CT looks like IPF - this is the same caution as in pure IPF management
This is a shared conversation. Sign in to Orris to start your own chat.